← All drugs
Drug · FAERS side-effect profile with label screen

Dextromethorphan Polistirex side effects: what 754 FDA adverse event reports show

Dextromethorphan Polistirex · 8 reaction terms · 94 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

754 reports · 11% serious · 11 with death outcome · 68% female

openFDA FAERS counts, all years, deduplication not applied

Used for

temporarily relieves • cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants • the impulse to cough to help you get to sleep

FDA label, Indications and Usage

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 7 strongest signals

Reporting / coding artifact 6No label text to screen 1
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug effect incomplete3425.7
18.5–35.6ROR 26.8 · χ² 782 / p 3e-172
25.3 EB05 18.9 · IC025 +3.7
3/3 methods agree
Reporting / coding artifact94% consumerno trial data cached
Product taste abnormal714.5
6.9–30.2ROR 14.6 · χ² 75 / p 3e-18
11.5 EB05 4.8 · IC025 +1.6
3/3 methods agree
Reporting / coding artifact–no trial data cached
Mydriasis613.0
5.9–28.9ROR 13.1 · χ² 55 / p 6e-14
9.4 EB05 3.8 · IC025 +1.3
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 14.2no trial data cached
Therapeutic response shortened1311.3
6.6–19.5ROR 11.5 · χ² 113 / p 1e-26
9.8 EB05 5.5 · IC025 +2.1
3/3 methods agree
Reporting / coding artifact–no trial data cached
Inappropriate schedule of drug administration186.9
4.4–10.9ROR 7.1 · χ² 86 / p 1e-20
6.0 EB05 4.0 · IC025 +1.8
3/3 methods agree
Reporting / coding artifact–no trial data cached
Incorrect product administration duration56.8
2.9–16.4ROR 6.9 · χ² 19 / p 5e-6
4.5 EB05 2.1 · IC025 +0.6
3/3 methods agree
Reporting / coding artifact–no trial data cached
Expired product administered75.9
2.8–12.3ROR 5.9 · χ² 24 / p 6e-7
4.4 EB05 2.3 · IC025 +0.8
3/3 methods agree
Reporting / coding artifact–no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug effect incomplete3425.7
18.5–35.6ROR 26.8 · χ² 782 / p 3e-172
25.3 EB05 18.9 · IC025 +3.7
3/3 methods agree
Reporting / coding artifact94% consumerno trial data cached
Inappropriate schedule of drug administration186.9
4.4–10.9ROR 7.1 · χ² 86 / p 1e-20
6.0 EB05 4.0 · IC025 +1.8
3/3 methods agree
Reporting / coding artifact–no trial data cached
Therapeutic response shortened1311.3
6.6–19.5ROR 11.5 · χ² 113 / p 1e-26
9.8 EB05 5.5 · IC025 +2.1
3/3 methods agree
Reporting / coding artifact–no trial data cached
Expired product administered75.9
2.8–12.3ROR 5.9 · χ² 24 / p 6e-7
4.4 EB05 2.3 · IC025 +0.8
3/3 methods agree
Reporting / coding artifact–no trial data cached
Product taste abnormal714.5
6.9–30.2ROR 14.6 · χ² 75 / p 3e-18
11.5 EB05 4.8 · IC025 +1.6
3/3 methods agree
Reporting / coding artifact–no trial data cached
Mydriasis613.0
5.9–28.9ROR 13.1 · χ² 55 / p 6e-14
9.4 EB05 3.8 · IC025 +1.3
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 14.2no trial data cached
Incorrect product administration duration56.8
2.9–16.4ROR 6.9 · χ² 19 / p 5e-6
4.5 EB05 2.1 · IC025 +0.6
3/3 methods agree
Reporting / coding artifact–no trial data cached
Incorrect drug administration duration43.9
1.5–10.4ROR 3.9 · χ² 6 / p 0.007
2.9 EB05 1.3 · IC025 -0.2
PRR-only: not supported by EBGM or IC
Reporting / coding artifact–no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Dextromethorphan Polistirex?

In FDA FAERS, the most frequently co-reported reaction terms for Dextromethorphan Polistirex are mydriasis. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Dextromethorphan Polistirex have an FDA boxed warning?

No. The FDA label retrieved for Dextromethorphan Polistirex has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Dextromethorphan Polistirex causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.